Athena Vale
Muscle wasting is a significant cause of morbidity and mortality in patients with cancer. Measuring muscle mass and changes in skeletal muscle is important to phenotype cachectic individuals and to monitor response to anti-cachectic treatments. There are several methods of assessing muscle wasting, including CT scans, cross-sectional imaging, and the use of biomarkers. However, simple anthropometric formulae are often unable to accurately predict muscularity.
| Characteristics | Values |
|---|---|
| Cachexia | Occurs commonly and is a significant cause of morbidity and up to 20% mortality in patients with cancer |
| Loss of muscle mass | A key element of the most recent consensus cachexia definition |
| Low muscle mass | Important to phenotype cachectic individuals and to monitor response to anti-cachectic treatments |
| Increased FSR in weight-losing patients with cancer | Compared with weight-stable patients and healthy controls |
| Poor specificity | 71% |
| Poor associations with known mechanisms of muscle wasting | Many of the potential protein/peptide markers identified |
| Marginal increase in skeletal muscle FSR | In weight-losing patients with cancer compared with weight-stable patients and healthy controls |
Explore related products
What You'll Learn
Using CT scans to measure muscle mass
CT scans are a useful tool for measuring muscle mass and assessing muscle wasting. They can provide a unique measure of muscularity that is associated with function, particularly in patients with cancer. Sequential CT scans can offer additional information about changes in body composition, even if there is no weight loss.
CT scans can be used in combination with estimates of skeletal muscle fractional synthetic rate (FSR) to assess the contribution of altered synthesis and degradation to muscle wasting. This combination of measurements can provide valuable insights into the mechanisms of muscle loss.
When assessing muscle wasting, it is important to consider regional variations in both muscle wasting and FSR. Different sites for measurement, such as the trunk (L3 CT) and limb muscle (quadriceps MRI), can be compared to determine the optimal site for evaluating muscle mass and function.
CT scans offer a relatively non-invasive method of assessing muscle mass. This is particularly advantageous when compared to more invasive procedures or methods that may be burdensome for patients. By quantifying muscle area on routine diagnostic cross-sectional imaging, healthcare professionals can obtain valuable information about regional and whole-body muscle mass.
Understanding Muscle Knots: Causes and Formation
You may want to see also
Explore related products
Measuring muscle protein kinetics
One way to measure muscle protein kinetics is through the use of sequential estimates of muscle mass from diagnostic CT scans, which can be combined with estimates of skeletal muscle fractional synthetic rate (FSR). This allows for the assessment of the contribution of altered synthesis and degradation to muscle wasting.
Another method is the use of a biomarker model, which can help identify potential protein/peptide markers associated with muscle wasting. However, further study is needed to determine the validity of these findings.
Additionally, trunk (L3 CT) and limb muscle (quadriceps MRI) cross-sectional measurements can be compared with functional assessments to determine the optimal site for measurement.
Overall, measuring muscle protein kinetics is an important tool in assessing muscle wasting and can provide valuable information for clinical or research settings.
Keto and Muscle Retention: What's the Science?
You may want to see also
Explore related products
Assessing the contribution of altered synthesis and degradation
There are significant regional variations in both muscle wasting and skeletal muscle fractional synthetic rate (FSR). The combination of sequential estimates of muscle mass from diagnostic CT scans along with estimates of FSR allows assessment of the contribution of altered synthesis and degradation to muscle wasting.
Despite a net loss of muscle as measured by serial CT scans, skeletal muscle FSR appeared to be marginally increased in weight-losing patients with cancer compared with weight-stable patients and healthy controls. When FSR was combined with measures of muscle mass, it was demonstrated that only small differences between synthesis and degradation are required to see the levels of muscle wasting seen in patients with cancer.
Routine cross-sectional imaging provides a useful and unique measure of muscularity that is associated with function in patients with cancer. Sequential scans can provide additional information about changes in body composition even in the absence of weight loss.
As different regional measures of muscularity are available, trunk (L3 CT) and limb muscle (quadriceps MRI) cross-sectional measurements were compared with functional assessments to determine the optimal site for measurement. A biomarker model for myosteatosis was developed with good sensitivity (97%) but poor specificity (71%). Many of the potential protein/peptide markers identified had poor associations with known mechanisms of muscle wasting and further study of the identified peptides in an extended cohort would help determine the validity of the present findings.
Activating Pec Muscles: Simple Strategies for Success
You may want to see also
Explore related products
Using biomarkers to identify muscle wasting
Muscle wasting, or cachexia, is a common condition that can cause significant morbidity and mortality in patients with cancer. It is characterised by a loss of muscle mass and low muscle mass is a key element of the cachexia definition. To phenotype cachectic individuals and monitor their response to anti-cachectic treatments, it is important to measure muscle mass and changes in skeletal muscle.
One way to assess muscle wasting is through the use of biomarkers. A biomarker model for myosteatosis was developed with good sensitivity (97%) but poor specificity (71%). Many of the potential protein/peptide markers identified had poor associations with known mechanisms of muscle wasting. However, two proteins with potential roles in muscle repair or neuromuscular function (Agarin and Cathepsin C) were identified and may warrant further investigation.
Another method to identify muscle wasting is through diagnostic imaging. Cross-sectional imaging offers a relatively non-invasive way to assess regional and whole-body muscle mass. Sequential CT scans can provide additional information about changes in body composition, even in the absence of weight loss. When combined with measures of muscle mass, these scans can demonstrate that only small differences between synthesis and degradation are required to see the levels of muscle wasting seen in patients with cancer.
Simple anthropometric formulae are unable to accurately predict muscularity when compared to estimates derived from imaging or other methods. Therefore, direct measurement of muscle mass is necessary to properly assess muscle wasting.
Elliptical Workouts: Burning Fat, Not Muscle
You may want to see also
Explore related products
Comparing trunk and limb muscle cross-sectional measurements
To assess muscle wasting, it is important to measure muscle mass and changes in skeletal muscle. This can be done through minimally invasive methods such as routine cross-sectional imaging, which provides a unique measure of muscularity that is associated with function in patients with cancer.
CT scans provide valuable information about muscle mass and can be used to monitor changes in body composition over time, even in the absence of weight loss. Sequential scans can help assess the contribution of altered synthesis and degradation to muscle wasting, as seen in patients with cancer.
Additionally, the identification of potential protein and peptide markers can aid in understanding muscle wasting. However, further study is needed to determine the validity of these markers and their association with known mechanisms of muscle wasting. By comparing trunk and limb muscle cross-sectional measurements, we can develop more accurate methods for assessing muscle wasting and its impact on different regions of the body.
The Muscularity of the Penis: Fact or Fiction?
You may want to see also
Frequently asked questions
Muscle wasting can be assessed by measuring muscle mass and changes in skeletal muscle. This can be done using CT scans and cross-sectional imaging.
Muscle wasting is the loss of muscle mass, which can occur as part of the cachexia wasting process. Cachexia is a significant cause of morbidity and mortality in patients with cancer.
Current methods of assessing muscle wasting, such as CT scans and cross-sectional imaging, are more accurate than simple anthropometric formulae, which can be inaccurate by up to 25%. However, there is still a need for more direct measurements of muscle mass.
A biomarker model for myosteatosis has been developed with good sensitivity (97%) but poor specificity (71%). Two proteins with potential roles in muscle repair or neuromuscular function, Agarin and Cathepsin C, have also been identified as potential biomarkers.
